Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. reported a profit distribution plan for the first half of 2025, proposing a cash dividend of 2.00 yuan per 10 shares to all shareholders, with no stock increase or bonus shares [1]. Company Overview - The total assets of the company at the end of the reporting period were approximately 10.96 billion yuan, a decrease of 1.55% compared to the end of the previous year [2]. - The net assets attributable to shareholders of the listed company increased by 2.04% to approximately 8.71 billion yuan [2]. - The operating income for the reporting period was approximately 2.87 billion yuan, reflecting a year-on-year increase of 3.86% [2]. - The total profit for the period was approximately 650.31 million yuan, an increase of 17.20% compared to the previous year [2]. - The net profit attributable to shareholders of the listed company was approximately 525.83 million yuan, representing a year-on-year increase of 10.70% [2]. - The net cash flow from operating activities was approximately 845.15 million yuan, a significant increase of 164.50% compared to the same period last year [2]. - The weighted average return on net assets was 6.02%, an increase of 0.48 percentage points from the previous year [2]. - Basic and diluted earnings per share were both 0.59 yuan, up 11.32% from the previous year [2]. - The total number of shareholders at the end of the reporting period was 53,672 [2]. Major Shareholders - The largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., is a domestic non-state-owned legal entity [3]. - Other significant shareholders include Taizhou Gede Industrial Co., Ltd. and individual shareholders such as Hua Lirong and Lin Huilu [3]. - There are noted relationships among some shareholders, indicating that certain individuals are acting in concert [3].

Key Points - The company plans to distribute a cash dividend of 0.20 RMB per share (including tax) to all shareholders, based on the total share capital as of June 30, 2025 [1][2] - The total share capital as of June 30, 2025, is 889,446,028 shares, with a total cash dividend amounting to 176,342,005.60 RMB (including tax) [1][2] - The total amount of cash dividends and share buybacks is 278,333,076.60 RMB, which accounts for 52.93% of the company's net profit attributable to shareholders for the first half of 2025 [2] - The board of directors approved the profit distribution plan during the 16th meeting of the 8th board on August 5, 2025, and it does not require further approval from the shareholders' meeting [2] - The supervisory board agrees that the profit distribution plan complies with relevant laws and regulations and does not harm the interests of shareholders, especially minority shareholders [2]

证券代码：603456 证券简称：九洲药业 公告编号：2025-049 浙江九洲药业股份有限公司 关于公司 2025 年半年度募集资金存放与使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为了规范募集资金的管理和使用，提高资金使用效率，保护投资者权益，浙 江九洲药业股份有限公司（以下简称"公司"）根据中国证券监督管理委员会《上 市公司募集资金监管规则》及《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》及相关格式指引的规定，将本公司 2025 年半年度募集资金存放与 使用情况专项报告公告如下： 一、募集资金基本情况 (一) 2020 年非公开发行募集资金情况 经中国证券监督管理委员会《关于核准浙江九洲药业股份有限公司非公开发 行股票的批复》 （证监许可[2021]97 号）核准，公司非公开发行人民币普通股（A 股 ） 股 票 26,171,159 股， 发 行价格 为 38.21 元 /股，募 集资金 总额为人 民 币 集资金净额为人民币 990,619,373.71 元。上述募集资金到位情况 ...

Core Viewpoint - The report outlines Zhejiang Jiuzhou Pharmaceutical Co., Ltd.'s commitment to enhancing quality and efficiency while returning value to shareholders through strategic initiatives and financial performance [1][2]. Group 1: Focus on Core Business and High-Quality Development - The company is an industry-leading CDMO enterprise, emphasizing innovation and customer service to support global drug development [1]. - In the first half of the year, the company achieved operating revenue of 2.871 billion yuan and a net profit attributable to shareholders of 526 million yuan [1]. - The company received multiple accolades, including being ranked among the top 20 Chinese pharmaceutical CDMO companies and receiving a "Gold Medal" certification from EcoVadis for corporate social responsibility [1]. Group 2: Continuous Cash Dividends and Shareholder Returns - The company prioritizes shareholder interests by consistently implementing cash dividends, distributing over 30% of the annual net profit since its listing in 2014 [2]. - For the 2024 annual profit distribution, the company plans to distribute 3.00 yuan per 10 shares, totaling approximately 265.76 million yuan, which represents 60.33% of the 2024 net profit [2]. - The mid-year profit distribution plan for 2025 proposes a dividend of 2.00 yuan per 10 shares, amounting to 52.93% of the mid-year net profit [2]. Group 3: Share Buyback Plans - The company intends to use between 100 million yuan and 200 million yuan for a share buyback program to enhance investor confidence and promote long-term stability [3]. - As of May 15, 2025, the company completed a buyback of 7,736,000 shares for a total payment of approximately 101.99 million yuan [3]. Group 4: Accelerating New Productive Forces - The company focuses on R&D innovation as a core driver of growth, leveraging its extensive experience in drug development and proprietary green pharmaceutical technologies [4][5]. - Collaborations with academic institutions have led to significant advancements in chemical synthesis and continuous reaction technologies [5]. Group 5: Enhancing Communication Channels and Company Value - The company aims to optimize information disclosure and improve investor relations by providing clear and accessible reports [6]. - Active participation in investor engagement activities, such as shareholder meetings and performance briefings, fosters trust and collaboration with investors [6]. Group 6: Strengthening Governance Mechanisms - The company adheres to legal regulations and continuously improves its governance practices to ensure effective operation [7]. - The company has received recognition for its ESG efforts, including being included in the FTSE Russell Social Responsibility Index and achieving a "Gold Medal" rating from EcoVadis [7].

浙江九洲药业股份有限公司 信息披露暂缓与豁免事务管理制度 浙江九洲药业股份有限公司 信息披露暂缓与豁免事务管理制度 第一章 总则 第一条 为规范浙江九洲药业股份有限公司（以下简称"公司"）和其他信息 披露义务人信息披露暂缓、豁免行为，加强信息披露监管，保护投资者合法权益， 根据《中华人民共和国保守国家秘密法》 《中华人民共和国证券法》 （以下简称《证 券法》）、 《上市公司信息披露管理办法》等法律、行政法规和规章，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会（以下简称"中国证监会"）和证 券交易所规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披 露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实施 内幕交易、操纵市场等违法行为。 第二章 信息披露暂缓与豁免的适用情形 第四条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事项， 履行内部审核程序后实施。 第五条 公司和其他信息披露义务人有确实充分的证据证明拟披露的信息涉 及国家秘密或者其他因披露可能 ...

华泰联合证券有限责任公司 关于浙江九洲药业股份有限公司 使用部分募集资金向募投项目实施主体增资 实施募投项目的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为浙江九洲药业股份有限公司（以下简称"九洲药业"或"公司"）非公开发行 股票持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》《上海证 券交易所股票上市规则》 《上市公司募集资金监管规则》 《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》等有关规定，对九洲药业本次使用部分募 集资金向募投项目实施主体增资实施募投项目进行审慎核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准浙江九洲药业股份有限公司非公开发 行股票的批复》（证监许可[2022]2955 号）核准，公司非公开发行人民币普通股 （A 股）股票 65,291,198 股，发行价格为 38.29 元/股，募集资金总额为人民币 募集资金净额为人民币 2,488,437,045.43 元。上述募集资金到位情况已经天健会 计师事务所（特殊普通合伙）审验，并于 2023 年 1 月 13 日出具天健验（2023） 为规范公司 ...

Investment Rating - The report assigns a "Buy-A" investment rating to the company [5] Core Views - The company is focused on building a leading innovative drug CDMO platform centered on technological innovation, providing comprehensive services to global pharmaceutical companies [13][21] - The sales of the company's key product, Entresto, have shown significant growth, with sales increasing from $507 million in 2017 to $7.822 billion in 2024, reflecting a CAGR of 47.83% [49] - The company is expanding its capabilities in peptide conjugates and small nucleic acid technologies, enhancing its TIDES business [2][50] Summary by Sections 1. Company Overview - The company specializes in small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drug R&D and production, offering a one-stop solution from preclinical CMC to commercialization [13] - The management team possesses international experience and a strong background in pharmaceuticals, which supports the company's expansion in the innovative drug CDMO sector [17] 2. Business Segments Small Molecule CDMO - The company has established a leading technology platform to support global pharmaceutical companies, particularly in supplying raw materials for key products like Entresto [3][49] Peptide Conjugate CDMO - The TIDES division is actively expanding its peptide production capacity, with significant investments made to meet growing customer demands [2][50] API Business - The company has strategically positioned itself in the market for specialty APIs, including anti-infectives, CNS drugs, NSAIDs, and antidiabetic drugs, with stable sales growth across these categories [3][55] 3. Financial Projections - The company is projected to achieve net profits of 921 million, 1.052 billion, and 1.158 billion yuan from 2025 to 2027, with respective growth rates of 52.0%, 14.2%, and 10.0% [4][62] - Revenue is expected to grow from 5.635 billion yuan in 2025 to 6.711 billion yuan in 2027, reflecting a steady increase in demand for its services [62] 4. Market Dynamics - The demand for CDMO services is anticipated to recover due to ongoing investments in innovative drug development, particularly in oncology, hypertension, and weight loss sectors [35] - The company has established long-term partnerships with major pharmaceutical firms, which provides a solid foundation for future growth [41]

Group 1: Company Performance - Jiuzhou Pharmaceutical reported a revenue of 2.871 billion yuan, an increase of 3.86% year-on-year [1] - The net profit attributable to shareholders was 526 million yuan, reflecting a year-on-year increase of 10.7% [1] - The basic earnings per share stood at 0.59 yuan [1] Group 2: CDMO Industry Insights - The global CDMO market is projected to reach $168.4 billion by 2028 and $338.5 billion by 2030 [2] - China's CDMO market has grown from 16 billion yuan in 2018 to 85.9 billion yuan in 2023, with a compound annual growth rate of 39.9% [2] - The market share of Chinese CDMO companies is increasing due to competitive advantages in talent supply, labor costs, and resource support [2] Group 3: Project Pipeline and Client Engagement - Jiuzhou Pharmaceutical has a robust project pipeline with 38 projects already on the market and 90 in Phase III clinical trials [1] - The company has successfully provided services to over 80 clients from major global pharmaceutical markets, covering more than 100 active formulation projects [2] - The company has introduced over 20 new clients in the peptide and conjugate business, with a focus on diabetes and cancer treatments [3] Group 4: Global Expansion and Operational Strategy - Jiuzhou Pharmaceutical is advancing its global R&D capabilities and production capacity, with successful business progress in Japan and Germany [3] - The company aims to accelerate its global business expansion and enhance collaborative efforts to drive sustainable growth [3]

（文章来源：证券日报） 证券日报网讯 8月5日晚间，九洲药业发布公告称，公司第八届监事会第十次会议审议通过了《关于公 司2025年半年度报告全文及摘要的议案》等多项议案。 ...

证券日报网讯 8月5日晚间，九洲药业发布公告称，公司第八届董事会第十六次会议审议通过了《关于 公司2025年半年度报告全文及摘要的议案》等多项议案。 （文章来源：证券日报） ...